We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Teva received final FDA approval for its nasal spray formulation of generic naloxone hydrochloride to stop or reverse the effects of an opioid overdose, the agency announced Friday.